血栓抽吸联合血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂在急性STEMI患者直接PCI中临床疗效的Meta分析

梁小雪; 吴倩怡; 夏勇; 吕籽; 罗素新

doi:10.13201/j.issn.1001-1439.2015.08.011

血栓抽吸联合血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂在急性STEMI患者直接PCI中临床疗效的Meta分析

- 1. 重庆医科大学附属第一医院心血管内科(重庆, 400016);
- 2. 美国俄亥俄州立大学医学院心肺研究所;
- 3. 四川华西临床学院
基金项目:
国家重点基础研究发展计划（No：2014CB542400）；国家自然科学基金面上项目（No：81270210，81170112）；重庆市科委课题（No：CSTC2012JJA10143）；国家临床重点专科建设项目经费资助[No：财社（2011）170号

详细信息

通讯作者: 罗素新,E-mail:luosuxin0204@163.com

中图分类号: R543.31

收稿日期: 2014-12-10

Clinical curative effect of thrombus aspiration combined with platelet glycoprotein Ⅱb/Ⅲa receptor inhibitor in the patients of acute STEMI undergoing PCI: a Meta-analysis

- 1. Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China;
- 2. DHLRI, The Ohio State University College of Medicine;
- 3. West China Medical School, Sichuan University

More Information

Corresponding author: LUO Suxin, E-mail: luosuxin0204@163.com

Received Date: 10 December 2014

摘要

摘要: 目的：评价血栓抽吸联合血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂（GPI）在急性STEMI患者直接PCI中的临床疗效。方法：计算机检索The Cochrane Library、PubMed、CNKI、万方数据库等关于急性STEMI患者直接PCI中应用血栓抽吸联合GPI的随机对照试验，按纳入与排除标准独立选择试验、资料提取和质量评价，对同质研究采用RevMan 5.2软件进行Meta分析。结果：最终纳入10项研究，共1 223例患者，分为试验组与对照组。Meta分析结果显示：与对照组相比，试验组主要心血管不良事件发生率（OR=0.55，95%CI：0.35~0.88，P=0.01）明显降低；TIMI 3级血流（OR=4.01，95%CI：2.55~6.32，P<0.01）及ST段回落情况（OR=2.55，95%CI：1.89~3.44，P<0.01）得到明显改善；试验组左室射血分数（OR=7.22，95%CI：6.03~8.42，P<0.01）优于对照组。结论：血栓抽吸联合GPI的应用可以明显降低急性STEMI患者MACE发生率，增加TIMI 3级血流，改善术后ST段回落情况及左室射血分数。
- 血栓抽吸 /
- 血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂 /
- 急性ST段抬高型心肌梗死 /
- 经皮冠状动脉介入治疗 /
- Meta分析
Abstract: Objective: To review the clinical curative effect of thrombus aspiration combined with platelet glycoprotein Ⅱb/Ⅲa receptor inhibitor(GPI) in the patients of acute STEMI undergoing PCI.Method: The databases of Cochrane Library, PubMed, CNKI, WanFang Database were retrieved with computer for researching randomized controlled trials about thrombus aspiration combined with GPI in the patients of acute STEMI undergoing PCI. The Meta-analysis was performed by using RevMan 5.2 software after extracted the data and evaluated the quality on the basis of inclusion and exclusion criteria.Result: There were totally 10 RCT included covering 1223 patients, spliting up into treatment group and control group. The results of Meta-analysis showed that compared with the control group, the incidence of major adverse cardiovascular events (MACE) (OR=0.55, 95%CI:0.35~0.88, P=0.01) was significantly reduced.The treatment group had improved TIMI 3 flow (OR=4.01, 95%CI:2.55~6.32, P<0.01) and ST-segment resolution(STR)(OR=2.55, 95%CI:1.89~3.44, P<0.01) in this study.Left ventricular ejection fraction(LVEF) (OR=7.22, 95%CI:6.03~8.42, P<0.01) in treatment group was obviously better than that in control group.Conclusion: Thrombus aspiration combined with GPI can obviously reduce the incidence of MACE, enhance the TIMI 3 flow, improve the STR and LVEF after PCI operation in the patients with acute STEMI.[HK]
- Thrombus aspiration /
- Platelet glycoprotein Ⅱb/Ⅲa receptor inhibitor /
- Acute ST-segment elevation myocardial infarction /
- Percutaneous coronary intervention /
- Meta-analysis

HTML全文

参考文献(20)

[1]	SARDELLA G, STIO R E.Thrombus aspiration in acute myocardial infarction:Rationale and indication[J].World J Cardiol, 2014.6:924-928.
[2]	FERGUSON J J, ZAQQA M.Platelet glycoprotein Ⅱb/Ⅲa receptor antagonists:current concepts and future directions[J].Drugs, 1999.58:965-982.
[3]	ECHAVARRÍA-PINTO M, LOPES R, GORGADZE T, et al.Safety and efficacy of intense antithrombotic treatment and percutaneous coronary intervention deferral in patients with large intracoronary thrombus[J].Am J Cardiol, 2013, 111:1745-1750.
[4]	LIU C P, LIN M S, CHIU Y W, et al.Additive benefit of glycoprotein Ⅱb/Ⅲa inhibition and adjunctive thrombus aspiration during primary coronary intervention:results of the Initial Thrombosuction and Tirofiban Infusion (ITTI) trial[J].Int J Cardiol, 2012, 156:174-179.
[5]	LIISTRO F, GROTTI S, ANGIOLI P, et al.Impact of thrombus aspiration on myocardial tissue reperfusion and left ventricular functional recovery and remodeling after primary angioplasty[J].Circ Cardiovasc Interv, 2009, 2:376-383.
[6]	SARDELLA G, MANCONE M, CANALI E, et al.Impact of thrombectomy with EXPort Catheter in Infarct-Related Artery during Primary Percutaneous Coronary Intervention (EXPIRA Trial) on cardiac death[J].Am J Cardiol, 2010, 106:624-629.
[7]	DE LUCA L, SARDELLA G, DAVIDSON C J, et al.Impact of intracoronary aspiration thrombectomy during primary angioplasty on left ventricular remodelling in patients with anterior ST elevation myocardial infarction[J].Heart, 2006, 92:951-957.
[8]	DE CARLO M, AQUARO G D, PALMIERI C, et al.A prospective randomized trial of thrombectomy versus no thrombectomy in patients with ST-segment elevation myocardial infarction and thrombus-rich lesions:MUSTELA (MUltidevice Thrombectomy in Acute ST-Segment ELevation Acute Myocardial Infarction) trial[J].JACC Cardiovasc Interv, 2012, 5:1223-1230.
[9]	LIU X, DONG P, XING S, et al.Clinical evaluation of thrombus aspiration combined with tirofiban in patients with acute myocardial infarction with elective percutaneous coronary intervention[J].J Int Med Res, 2013, 41:1532-1540.
[10]	STONE G W, WITZENBICHLER B, GODLEWSKI J, et al.Intralesional abciximab and thrombus aspiration in patients with large anterior myocardial infarction:one-year results from the INFUSE-AMI trial[J].Circ Cardiovasc Interv, 2013, 6:527-534.
[11]	吴桥, 陈多学, 江荣炎, 等.血栓抽吸联合替罗非班在急性ST段抬高型心肌梗死直接经皮冠状动脉介入治疗中的应用评价[J].淮海医药, 2012, 30(6):498-500.
[12]	简立国, 刘士超, 王鹏飞, 等.血栓抽吸导管联合替罗非班对急性ST段抬高型心肌梗死恢复心肌"再灌注"的近期临床疗效观察[J].中国循环杂志, 2014, 29(7):501-504.
[13]	陈玉善, 解金红, 罗明华, 等.介入治疗联合经血栓抽吸导管冠状动脉内应用替罗非班对急性心肌梗死患者的效果[J].疑难病杂志, 2014, 13(5):456-459.
[14]	NICCOLI G, BURZOTTA F, GALIUTO L, et al.Myocardial no-reflow in humans[J].J Am Coll Cardiol, 2009, 54:281-292.
[15]	KUMBHANI D J, BAVRY A A, DESAI M Y, et al.Aspiration thrombectomy in patients undergoing primary angioplasty:Totality of data to 2013[J].Catheter Cardiovasc Interv, 2014, 84:973-977.
[16]	MONTALESCOT G, WIVIOTT S D, BRAUNWALD E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38):double-blind, randomised controlled trial[J]. Lancet, 2009, 373:723-731.
[17]	DZIEWIERZ A, RAKOWSKI T, DUDEK D.Abciximab in the management of acute myocardial infarction with ST-segment elevation:evidence-based treatment, current clinical use, and future perspectives[J].Ther Clin Risk Manag, 2014, 10:567-576.
[18]	XU Q, YIN J, SI L Y.Efficacy and safety of early versus late glycoprotein IIb/IIIa inhibitors for PCI[J].Int J Cardiol, 2013, 162:210-209.
[19]	QIN T, XIE L, CHEN M H.Meta-analysis of randomized controlled trials on the efficacy and safety of intracoronary administration of tirofiban for no-reflow phenomenon[J].BMC Cardiovasc Disord, 2013, 13:68.
[20]	VLAAR P J, SVILAAS T, VAN DER HORST I C, et al.Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS):a 1-year follow-up study[J].Lancet, 2008, 371:1915-1920.